Your browser doesn't support javascript.
loading
[Strategies and advances in laboratory tests for primary liver cancer].
Chen, Y; Liang, J; Li, Y H; Wang, Y J.
Afiliação
  • Chen Y; Department of Clinical Laboratory, Peking University Ditan Teaching Hospital, Beijing 100015, China.
  • Liang J; Department of Clinical Laboratory, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
  • Li YH; Department of Clinical Laboratory, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
  • Wang YJ; Department of Clinical Laboratory, Peking University Ditan Teaching Hospital, Beijing 100015, China Department of Clinical Laboratory, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Zhonghua Yu Fang Yi Xue Za Zhi ; 58(1): 128-135, 2024 Jan 06.
Article em Zh | MEDLINE | ID: mdl-38228560
ABSTRACT
Primary liver cancer is one of the leading causes of cancer-related deaths worldwide, its early diagnosis and early treatment are of great clinical importance. The main detection tools for liver cancer include serological indicators, imaging tests and risk assessment models. With the advancement of technology and research, the sensitivity and specificity of laboratory tests for liver cancer have been substantially improved, but there are still false negatives and low rates of early diagnosis. For different causes and prevalence regions, each country has developed its clinical practice guidelines to guide risk groups for effective prevention, early diagnosis and standardized treatment. It is important to establish a liver cancer diagnosis strategy that is suitable for China's national conditions, concerning the guidelines for the vigilance and prevention of liver cancer. In this article, the advantages and disadvantages of liver cancer-related tests and the impact of future development trends on laboratory strategies are explained from the perspective of laboratory testing strategies, to provide theoretical support for the practical application of liver cancer diagnostic strategies.
Assuntos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Hepáticas Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans Idioma: Zh Revista: Zhonghua Yu Fang Yi Xue Za Zhi Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Hepáticas Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans Idioma: Zh Revista: Zhonghua Yu Fang Yi Xue Za Zhi Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China